Monday, May 25 2026

Deregulation of non-essential medicines leads to 34pc increase in pharma exports
Deregulation of non-essential medicines in 2024 has led to a 34 percent increase in pharmaceutical exports, improved medicine availability, expansion of internationally certified manufacturing facilities and higher tax contributions, while any reversal of the policy could result in an industrial crisis and loss of investor confidence, pharmaceutical industry officials said. According to industry estimates, pharmaceutical exports increased from around USD336 million before deregulation to nearly USD450 million in 2025, while manufacturers also expanded investment in WHO, PIC/S and EU GMP compliant facilities aimed at accessing regulated international markets.
Related news categories: business economic-indicators misc pharma

Tuesday, May 12 2026

Pakistani pharma Searle to transfer biologic portfolio to Nextar
The Searle Company Limited on Tuesday announced a major restructuring plan aimed at consolidating its biological products business under a dedicated subsidiary, as part of efforts to streamline operations and improve efficiency across the group. The listed pharma shared this development in a notice to the Pakistan Stock Exchange (PSX). The pharma said that its board had approved a proposal to recommend an investment of up to Rs4 billion into the share capital of its indirect subsidiary, Nextar Pharma (Private) Limited. The notice further stated that the investment would be made indirectly through the company’s wholly owned subsidiary, Searle BioSciences (Pvt) Limited, and is intended to facilitate the acquisition of the company’s biological and associated products portfolio.
Related news categories: business economic-indicators pharma psx stock-exchanges

Friday, May 08 2026

Medicine prices: Senate body directs CCP to review hike
The Senate Standing Committee on National Health Services and Regulations on Thursday advanced on major health reforms and pharmaceutical deregulation strategies. The Senate body also directed the Competition Commission of Pakistan (CCP) to review the matter of the recent hike in medicine prices. The standing committee met here under the chairmanship of Senator Amir Waliuddin Chishti to deliberate on critical legislative amendments and sector-wide performance reviews aimed at modernizing Pakistan’s healthcare infrastructure and regulatory frameworks. It emphasized that while private investment is appreciated, it must not come out of the poor and general public’s money.
Related news categories: business economic-indicators misc pharma